Publications by authors named "A Chincarini"
β-amyloid-targeting antibodies represent the first generation of effective causal treatment of Alzheimer's disease (AD) and can be considered historical research milestones. Their effect sizes, side effects, implementation challenges and costs, however, have stimulated debates about their overall value. In this position statement academic clinicians of the European Alzheimer's Disease Consortium (EADC) discuss the critical relevance of introducing these new treatments in clinical care now.
View Article and Find Full Text PDFArticle Synopsis
- Apathy unawareness in mild cognitive impairment (MCI) is linked to differences between caregiver and patient assessments, potentially predicting progression to Alzheimer's dementia.
- Researchers studied 28 MCI patients, using the Apathy Evaluation Scale to gauge apathy levels from both perspectives, and analyzed brain activity via PET scans.
- Findings revealed that greater discrepancies in assessments correlated with lower metabolism in specific brain regions, indicating that apathy unawareness is tied to early limbic system disruptions rather than traditional pathways associated with apathy.
Anterior Visual Pathway (aVP) damage may be linked to diverse inflammatory, degenerative and/or vascular conditions. Currently however, a standardized methodological framework for extracting MRI biomarkers of the aVP is not available. We used high-resolution, 3-D MRI data to generate a probabilistic anatomical atlas of the normal aVP and its intraorbital (iOrb), intracanalicular (iCan), intracranial (iCran), optic chiasm (OC), and tract (OT) subdivisions.
View Article and Find Full Text PDFBackground: Neuronal pentraxin-2 (NPTX2), crucial for synaptic functioning, declines in cerebrospinal fluid (CSF) as cognition deteriorates. The variations of CSF NPTX2 across mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and its association with brain metabolism remain elusive, albeit relevant for patient stratification and pathophysiological insights.
Methods: We retrospectively analyzed 49 MCI-AD patients grouped by time until dementia (EMCI, n = 34 progressing within 2 years; LMCI, n = 15 progressing later/stable at follow-up).